NexMed garners Japanese patent

June 2010
Medical Device Daily;6/28/2010, Vol. 14 Issue 123, p7
The article reports on the decision of Japan's Patent Office to approve NexMed's patent "Prostaglandin Composition for the Treatment of Male Erectile Dysfunction."


Related Articles

  • NexMed's U.S. patent triggers a milestone payment from Novartis.  // Medical Device Daily;10/29/2008, Vol. 12 Issue 211, p8 

    The article reports that the U.S. Patent & Trademark Office has issued a notice of allowance for NexMed's U.S. patent application titled, "Antifungal Nail Coat and Method of Use." The patent covers NM100060, a topical application of terbinafine formulated with NexACT for the treatment of...

  • Genitourinary News Round-Up.  // PharmaWatch: Monthly Review;Aug2010, Vol. 9 Issue 8, p10 

    The article offers news briefs related to firms involved in drug development for genitourinary diseases. The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries Ltd.''s Anastrozole tablets. The U.S. rights of Columbia Laboratories Inc.'s Crinone and Prochieve...

  • NexMed Completes Study on Topical Impotence Treatment.  // Worldwide Biotech;Oct99, Vol. 11 Issue 10, p1 

    Reports on the announcement of NexMed Inc. on the evaluation of its proprietary alprostadil cream for treating male erectile dysfunction (MED) in a multiple-use clinical study in China that involved patients afflicted with MED. Results of the clinical study; Comments from Doctor Y. Joseph Mo,...

  • NexMed reports net loss for second quarter.  // Biotech Financial Reports;Oct99, p4 

    Reports on Robbinsville, New Jersey-based NexMed Inc.'s announcement of its revenue for the quarter ended June 30, 1999. Total net loss; Total sale from its joint venture operations in China; Information on the company.

  • NEXMED DEVELOPING TREATMENT FOR PREMATURE EJACULATION.  // Biotech Business;Sep2003, Vol. 16 Issue 9, p4 

    Reports the progress in the topical treatment for premature ejaculation development project of NexMed Inc., a developer of innovative transdermal treatments based on its NexACT proprietary drug delivery technology.

  • INVEST NEW JERSEY. McKnight, Marshall // Business News New Jersey;12/05/2000, Vol. 13 Issue 49, p16 

    Focuses on the increased stock prices of New Jersey-based NexMed Inc. Growth of stock value following the completion of the Phase III of the company's Befar erectile dysfunction cream.

  • Bio-Quant Successor Attracts $2.3M Investment. Chambers, Heather // San Diego Business Journal;2/15/2010, Vol. 31 Issue 7, p5 

    The article reports on the 2.3 million U.S. dollars promissory notes raised by NexMed Inc. from two investors in connection to its acquisition of San Diego-based Bio-Quant Inc.

  • Financings Roundup.  // BioWorld Today;5/15/2008, Vol. 19 Issue 95, p3 

    The article reports on a binding commitment entered by NexMed Inc. of East Windsor, New Jersey with one of its largest shareholders for a line of credit. The company intends to use the money to bridge the anticipated payments from partner Novartis AG, which licensed rights to NM100060 of NexMed....

  • NexMed Shares Fall Hard as Novartis Nixes NDA. Hollingsworth, Catherine // BioWorld Today;8/28/2008, Vol. 19 Issue 168, p1 

    The article reports on a decline in the value of NexMed's shares by 81.6% after its partner, Novartis AG, decided not to file for a new drug application for a topical nail fungus product that uses NexMed's drug delivery technology. Such decision by Novartis was attributed to a negative Phase III...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics